22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Bio-Rad Laboratories, Inc. › 2024-2025

Bio-Rad Laboratories, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 25, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 129Asset managers, any item
  • 1,642Fund votes
  • April 22, 2025Meeting date

Results at a glance

Meeting of April 22, 2025: 8 items on Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 25, 2025: 1 approved · 6 passed (calculated) · 1 not approved.

Dissent

Notable dissent: 2 directors (19.0%, 17.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Bio-Rad Laboratories, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Bio-Rad Laboratories, Inc.

These tallies are Bio-Rad Laboratories, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 25, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Bio-Rad Laboratories, Inc. — official shareholder meeting results, meeting held April 22, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Melinda Litherland 16,693,5883,918,47810,596 --1,195,004 81%Passed (calculated)—
Elect Director: Arnold A. Pinkston 17,013,7653,598,33110,566 --1,195,004 83%Passed (calculated)—
Elect Director: Jeffrey L. Edwards 4,989,57734191 --33,701 99.9%Passed (calculated)—
Elect Director: Gregory K. Hinckley 4,989,57734191 --33,701 99.9%Passed (calculated)—
Elect Director: Allison Schwartz 4,988,4651,45391 --33,701 99.9%Passed (calculated)—
Elect Director: Norman Schwartz 4,988,4651,45391 --33,701 99.9%Passed (calculated)—
2. Proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2025 7,151,39151,9102,176 ---- 99.3%Approveda majority of the shares outstanding
3. Stockholder proposal requesting approval of certain executive severance arrangements 923,2156,125,7843,277 --153,201 13%Not approveda majority of the shares outstanding

Source: Bio-Rad Laboratories, Inc., Form 8-K, filed with the SEC on April 25, 2025 — read the filing on EDGAR.

How asset managers voted at the Bio-Rad Laboratories, Inc. 2024-2025 meeting

129 asset managers disclosed a vote on at least one Bio-Rad Laboratories, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Arnold A. Pinkston

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST
FOR: 17,013,765AGAINST: 3,598,331

Prior year: 88.5% for (April 23, 2024 meeting) ▼ 6.0 pts

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: Nominees: Arnold A. Pinkston

Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Arnold A. Pinkston”): 17,013,765 for, 3,598,331 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 6,701,038 for, 1,972,796 against, 3,601 abstained.

FORAGAINST
FOR: 6,701,038AGAINST: 1,972,796ABSTAIN: 3,601
Largest asset managers voting on “Nominees: Arnold A. Pinkston” at Bio-Rad Laboratories, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,909,2380 00For
VanEck ETF Trust01,134,115 00Against
FIRST EAGLE FUNDS1,052,8560 00For
BlackRock873,4080 00For
Dimensional656,4150 00For
ARIEL INVESTMENT TRUST353,1430 00For
Fidelity308,32012,353 00For
Parnassus0318,111 00Against
LONGLEAF PARTNERS FUNDS TRUST202,8960 00For
Charles Schwab0195,069 00Against
Investment Managers Series Trust III157,1180 00For
State Street1,968127,498 00Against
Jackson National128,4410 00For
Allspring121,1230 00For
John Hancock111,3570 00For
Transamerica104,3770 00For
HARBOR FUNDS70,1530 00For
Putnam059,707 00Against
Equitable27,99022,878 00Mixed
Artisan48,0180 00For
TRUST FOR PROFESSIONAL MANAGERS43,0820 00For
FRANKLIN VALUE INVESTORS TRUST041,406 00Against
Gabelli40,3000 00For
TIAA37,9820 00For
Brighthouse34,4810 00For

Showing the 25 largest of 122 asset managers. All 122 are in the interactive database (link above).

Elect Director: Melinda Litherland

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST
FOR: 16,693,588AGAINST: 3,918,478

Prior year: 87.3% for (April 23, 2024 meeting) ▼ 6.4 pts

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: Nominees: Melinda Litherland

Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Melinda Litherland”): 16,693,588 for, 3,918,478 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 6,432,077 for, 2,241,757 against, 3,601 abstained.

FORAGAINST
FOR: 6,432,077AGAINST: 2,241,757ABSTAIN: 3,601
Largest asset managers voting on “Nominees: Melinda Litherland” at Bio-Rad Laboratories, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,909,2380 00For
VanEck ETF Trust01,134,115 00Against
FIRST EAGLE FUNDS1,052,8560 00For
BlackRock873,4080 00For
Dimensional656,4150 00For
ARIEL INVESTMENT TRUST353,1430 00For
Fidelity39,359281,314 00Mixed
Parnassus0318,111 00Against
LONGLEAF PARTNERS FUNDS TRUST202,8960 00For
Charles Schwab0195,069 00Against
Investment Managers Series Trust III157,1180 00For
State Street1,968127,498 00Against
Jackson National128,4410 00For
Allspring121,1230 00For
John Hancock111,3570 00For
Transamerica104,3770 00For
HARBOR FUNDS70,1530 00For
Putnam059,707 00Against
Equitable27,99022,878 00Mixed
Artisan48,0180 00For
TRUST FOR PROFESSIONAL MANAGERS43,0820 00For
FRANKLIN VALUE INVESTORS TRUST041,406 00Against
Gabelli40,3000 00For
TIAA37,9820 00For
Brighthouse34,4810 00For

Showing the 25 largest of 122 asset managers. All 122 are in the interactive database (link above).

Proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.3% Approved · of votes cast

FOR 99.3%
FOR: 7,151,391AGAINST: 51,910

Prior year: 99.3% for (April 23, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.

Bio-Rad Laboratories, Inc.’s own tally for this item (“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2025”): 7,151,391 for, 51,910 against — passed, per its Form 8-K filed April 25, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2025 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes …”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR
Largest asset managers voting on “Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.” at Bio-Rad Laboratories, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,909,2380 00For
VanEck ETF Trust1,134,1150 00For
FIRST EAGLE FUNDS1,052,8560 00For
BlackRock873,4080 00For
Dimensional656,4150 00For
ARIEL INVESTMENT TRUST353,1430 00For
Fidelity320,6730 00For
Parnassus318,1110 00For
LONGLEAF PARTNERS FUNDS TRUST202,8960 00For
Charles Schwab195,0690 00For
Investment Managers Series Trust III157,1180 00For
State Street129,4606 00For
Jackson National128,4410 00For
Allspring121,1230 00For
John Hancock111,3570 00For
Transamerica104,3770 00For
HARBOR FUNDS70,1530 00For
Putnam59,7070 00For
Equitable50,8680 00For
Artisan48,0180 00For
TRUST FOR PROFESSIONAL MANAGERS43,0820 00For
FRANKLIN VALUE INVESTORS TRUST41,4060 00For
Gabelli40,4500 00For
TIAA37,9820 00For
Brighthouse34,4810 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Stockholder proposal requesting approval of certain executive severance arrangements

Official resultFund totals may overlapCOMPENSATIONReported outcome: Not approved

Combines 4 wordings of this item as funds reported it.

13% Not approved · of votes cast

13%AGAINST
FOR: 923,215AGAINST: 6,125,784
Details: description as filed, official tally, votes by 121 asset managers

Description as filed by funds: Stockholder proposal requesting approval of certain executive severance arrangements.

Bio-Rad Laboratories, Inc.’s own tally for this item (“3. The stockholder proposal requesting approval of certain executive severance arrangements”): 923,215 for, 6,125,784 against — failed, per its Form 8-K filed April 25, 2025 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The stockholder proposal requesting approval of certain executive severance arrangements was not approved since the proposal did not receive the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock”
Support: 13% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Also reported under other wordings, matched to the same row of Bio-Rad Laboratories, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Shareholder Proposal Regarding Severance Approval Policy” (2 managers, 2,283 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 116 asset managers voting on “Stockholder proposal requesting approval of certain executive severance arrangements.” at Bio-Rad Laboratories, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard01,909,238 00Against
VanEck ETF Trust1,134,1150 00For
FIRST EAGLE FUNDS3,4731,049,383 00Against
BlackRock0873,408 00Against
Dimensional656,4150 00For
ARIEL INVESTMENT TRUST0353,143 00Against
Fidelity306,58914,084 00For
Parnassus318,1110 00For
LONGLEAF PARTNERS FUNDS TRUST0202,896 00Against
Charles Schwab0195,069 00Against
Investment Managers Series Trust III157,1180 00For
State Street1,955127,511 00Against
Jackson National4,954123,487 00Against
Allspring121,1230 00For
John Hancock111,3570 00For
Transamerica104,3770 00For
HARBOR FUNDS70,1530 00For
Putnam59,7070 00For
Equitable22,87827,990 00Mixed
Artisan48,0180 00For
TRUST FOR PROFESSIONAL MANAGERS42,752330 00For
FRANKLIN VALUE INVESTORS TRUST41,4060 00For
Gabelli040,450 00Against
TIAA37,9820 00For
Brighthouse34,4810 00For

No total is shown for the fund voting reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “Stockholder proposal requesting approval of certain executive severance arrangements.” at Bio-Rad Laboratories, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
QVIDTVM Management LLC0125,830 00Against
AYAL Capital Advisors Ltd13,5950 00For
MITCHELL & PAHL PRIVATE WEALTH, LLC0127 00Against
Fortitude Family Office, LLC02 00Against

Institutional-manager reports, all 4 managers: 13,595 for, 125,959 against.

Largest Bio-Rad Laboratories, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 27,941,000 shares outstanding at the time of that meeting.

Fund voting reports: top Bio-Rad Laboratories, Inc. shareholders by shares voted on “Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 6.83%
2VanEck ETF Trust 4.06%
3FIRST EAGLE FUNDS 3.77%
4BlackRock 3.13%
5Dimensional 2.35%
6ARIEL INVESTMENT TRUST 1.26%
7Fidelity 1.15%
8Parnassus 1.14%
9LONGLEAF PARTNERS FUNDS TRUST 0.73%
10Charles Schwab 0.70%
Institutional-manager reports: top Bio-Rad Laboratories, Inc. shareholders by shares voted on “Stockholder proposal requesting approval of certain executive severance arrangements.”, 2024-2025
#Asset manager % of shares outstanding
1QVIDTVM Management LLC 0.45%
2AYAL Capital Advisors Ltd 0.05%
3MITCHELL & PAHL PRIVATE WEALTH, LLC <0.01%
4Fortitude Family Office, LLC <0.01%

Reported Bio-Rad Laboratories, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Bio-Rad Laboratories, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Norman D. Schwartz3,228,922 11.56%Schedule 13D, filed October 30, 2025
BIO-RAD LABORATORIES, INC2,764,078 9.89%Schedule 13G, filed March 4, 2025
Alice N. Schwartz2,732,073 9.78%Schedule 13D, filed July 18, 2025
BlackRock2,021,720 7.24%Form 13F, quarter ended March 31, 2025
Vanguard Group1,912,157 6.84%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors877,040 3.14%Form 13F, quarter ended March 31, 2025
State Street694,520 2.49%Form 13F, quarter ended March 31, 2025
Geode Capital342,943 1.23%Form 13F, quarter ended March 31, 2025
Millennium Management336,052 1.20%Form 13F, quarter ended March 31, 2025
Northern Trust261,122 0.93%Form 13F, quarter ended March 31, 2025

Percentages above are of 27,941,000 shares outstanding, as reported by Bio-Rad Laboratories, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Bio-Rad Laboratories, Inc.'s shareholder meeting held April 22, 2025, in the 2024-2025 proxy season, 129 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,642 separate fund positions. On the most widely held item on that ballot — Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors. — Bio-Rad Laboratories, Inc.'s filing reports the proposal as approved, with 99.3% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Bio-Rad Laboratories, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 25, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Bio-Rad Laboratories, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Bio-Rad Laboratories, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Bio-Rad Laboratories (BIO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/bio-rad-laboratories-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.